. . . . . "# Nordstrom AL, Mansson M, Jovanovic H, Karlsson P, Halldin C, Farde L, Vanover KE, Hacksell U, Brann MR, Davis RE, Weiner DM: PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain. Int J Neuropsychopharmacol. 2007 Aug 21;:1-9. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17708779"@en . . . . . . . . . "investigational"@en . "Investigated for use/treatment in neurologic disorders, parkinson's disease, psychosis, schizophrenia and schizoaffective disorders, and sleep disorders."@en . . . . . . "ACP-103 reduces haloperidol-induced akathisia, a debilitating extrapyramidal side effect (EPS), in patients with schizophrenia. ACP-103 is a 5-HT2A inverse agonist, to reduce the side effects associated with antipsychotic drug treatment with haloperidol. ACP-103 reduced both the motor disturbances and hyperprolactinemia, a condition of elevated prolactin secretion, caused by haloperidol treatment."@en . . "ACP-103 is a potent and selective 5-HT2A inverse agonist, as a co-therapy for schizophrenia. ACP-103 is a novel therapy for schizophrenia to be used in combination with currently available antipsychotic drugs including haloperidol, Zyprexa, Risperdal and Seroquel. "@en . . . . . "ACP-103"@en . . . . . .